These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31358900)

  • 1. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
    He Y; Johnson DT; Yang JS; Wu H; You S; Yoon J; Lee DH; Kim WK; Aldahl J; Le V; Hooker E; Yu EJ; Geradts J; Cardiff RD; Sun Z
    Oncogene; 2019 Sep; 38(38):6507-6520. PubMed ID: 31358900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
    Lee DH; Yu EJ; Aldahl J; Yang J; He Y; Hooker E; Le V; Mi J; Olson A; Wu H; Geradts J; Xiao GQ; Gonzalgo ML; Cardiff RD; Sun Z
    PLoS One; 2019; 14(1):e0211153. PubMed ID: 30677079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
    J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
    PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.
    Lee SH; Luong R; Johnson DT; Cunha GR; Rivina L; Gonzalgo ML; Sun Z
    Oncogene; 2016 Feb; 35(6):702-14. PubMed ID: 25893287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis.
    He Y; Mi J; Olson A; Aldahl J; Hooker E; Yu EJ; Le V; Lee DH; Kim WK; Robins DM; Geradts J; Sun Z
    Oncogene; 2020 Apr; 39(16):3276-3291. PubMed ID: 32089544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate.
    Zhu C; Luong R; Zhuo M; Johnson DT; McKenney JK; Cunha GR; Sun Z
    J Biol Chem; 2011 Sep; 286(38):33478-88. PubMed ID: 21795710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
    Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.
    Vinall RL; Chen JQ; Hubbard NE; Sulaimon SS; Shen MM; Devere White RW; Borowsky AD
    Dis Model Mech; 2012 Nov; 5(6):914-20. PubMed ID: 22563073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
    Thompson VC; Day TK; Bianco-Miotto T; Selth LA; Han G; Thomas M; Buchanan G; Scher HI; Nelson CC; ; Greenberg NM; Butler LM; Tilley WD
    Int J Cancer; 2012 Aug; 131(3):662-72. PubMed ID: 22275114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells.
    He Y; Hooker E; Yu EJ; Cunha GR; Liao L; Xu J; Earl A; Wu H; Gonzalgo ML; Sun Z
    Oncogene; 2019 Mar; 38(13):2337-2350. PubMed ID: 30510232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
    Wu M; Ingram L; Tolosa EJ; Vera RE; Li Q; Kim S; Ma Y; Spyropoulos DD; Beharry Z; Huang J; Fernandez-Zapico ME; Cai H
    J Biol Chem; 2016 Dec; 291(49):25749-25760. PubMed ID: 27760825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
    Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
    Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.
    Wang Y; Radhakrishnan D; He X; Peehl DM; Eng C
    J Clin Endocrinol Metab; 2013 Mar; 98(3):E586-94. PubMed ID: 23386643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
    Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
    J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation of the androgen receptor causes oncogenic transformation of the prostate.
    Ratliff TL
    J Urol; 2005 Sep; 174(3):1149. PubMed ID: 16094083
    [No Abstract]   [Full Text] [Related]  

  • 18. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.
    Shin S; Kim TD; Jin F; van Deursen JM; Dehm SM; Tindall DJ; Grande JP; Munz JM; Vasmatzis G; Janknecht R
    Cancer Res; 2009 Oct; 69(20):8102-10. PubMed ID: 19789348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tumor suppressor dysregulation in prostate cancer progression.
    Dean JL; Knudsen KE
    Curr Drug Targets; 2013 Apr; 14(4):460-71. PubMed ID: 23410128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.